This website uses cookies to ensure you get the best experience on our website. Privacy Policy
UroToday UroToday
  • Contact
  • Login
  • Sign Up Free
  • Transformative Evidence
    • mCRPC
      • The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
      • PROfound
      • VISION Trial
    • mHSPC
      • ARASENS Trial
    • nmCRPC
      • ARAMIS Trial
    • PSMA PET Imaging
      • CONDOR Trial
      • OSPREY Trial
    • Bladder Cancer
      • Bladder Cancer Detection
  • Trials in Progress
    • Trials in Progress
      • Bladder Cancer
        • IMMORTAL
      • Kidney Cancer
        • RadiCal
    • Middle Side
      • Prostate Cancer
        • ARAMON
        • ARASEC
        • ARASTEP
        • ECLIPSE
        • FORT
        • NRG-GU 0101
        • Masofaniten (Oral EPI-7386)
        • RTIRE
        • SHORTER
        • SPLASH
    • Right Side
      • PCCTC
        • DORA
        • IRONMAN
        • PROMISE
  • Centers of Excellence
    • Urologic Oncology
      • Left Group
        • Health Policy
          • Health Policy
            Ruchika Talwar, MD
        • Bladder Cancer
          • Bladder Cancer
            Ashish Kamat, MD
          • Advanced Bladder Cancer
            Petros Grivas, MD
          • Trimodality Therapy
            Leslie Ballas, MD
        • Kidney Cancer
          • Advanced Kidney Cancer
            Pedro Barata, MD, MSc
          • Kidney Cancer Today
            Sumanta (Monty) Kumar Pal, MD
            Jaime Landman, MD
      • Prostate Cancer
        • Advanced Prostate Cancer
          Alicia Morgans, MD, MPH
        • CRPC with Bone Metastases
          Rana R. McKay, MD
        • Imaging Center
          Phillip Koo, MD
        • Localized Prostate Cancer
          Matthew R. Cooperberg, MD, MPH
        • mHSPC
          Alicia Morgans, MD, MPH
        • nmCRPC
          Alicia Morgans, MD, MPH
        • PSMA-Targeted Therapy
      • Disparities: Social Determinants of Health
        • Disparities: Social Determinants of Health
          Samuel L. Washington III, MD, MAS
      • Translational Prostate Cancer
        • Translational Science in Prostate Cancer
          Andrea Miyahira, Ph.D
        • Women in Science
          Andrea Miyahira, Ph.D
      • Upper Tract Urothelial Carcinoma
        • Upper Tract Urothelial Carcinoma
          Sam S. Chang, MD, MBA
      • TESTICULAR, PENILE & RARE GU MALIGNANCIES
        • Testicular, Penile, and Rare GU Malignancies
    • Pelvic Health & Reconstruction
      • Bladder Health
        Diane K. Newman, DNP, ANP-BC, FAAN
      • Pelvic Health
        Diane K. Newman, DNP, ANP-BC, FAAN
      • Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
        Stephen R. Kraus, MD
      • Urologic Catheters (Includes CAUTI)
        Diane K. Newman, DNP, ANP-BC, FAAN
      • Suprapubic Catheter
        Diane K. Newman, DNP FAAN BCB-PMD
  • Videos
    • Exclusives
      • Conferences
      • Exclusive Collaborations
      • Independent Medical Education
      • Covid-19
      • The Prostate Cancer Foundation
    • Urologic Oncology
      • Prostate Cancer
      • Bladder Cancer
      • Kidney Cancer
      • Upper Tract Urothelial Tumors
      • Pelvic Health & Reconstruction
      • Endourology
      • Testicular Cancer
      • Health Policy in Urological Diseases
      • Disparities: Social Determinants of Health
  • Clinical Trials
    • From the Editor
      • Search Clinical Trials
  • Articles
    • Urology (benign and malignant)
      • Urologic Oncology
      • Men's Health
      • Endourology & Stones
      • Pediatric Urology
      • COVID-19 and Genitourinary Cancers
    • Pelvic Health
      • Pelvic Health & Reconstruction
  • Conference Coverage
    • Recent Conferences
      • IBCN 2023
      • ASTRO 2023
      • SNMMI 2023
      • ASCO 2023
      • AUA 2023
    • All Conferences
      • View All
  • PCF
  1. UroToday Home
  2. Recent Abstracts
  3. Urologic Oncology

Prostate Cancer

Recent Abstracts
Polysaccharide-K augments docetaxel-induced tumor suppression and antitumor immune response in an immunocompetent murine model of human prostate cancer - Abstract February 3, 2012
Epigenetics in prostate cancer - Abstract February 3, 2012
Chemoprevention of prostate cancer: Natural compounds, antiandrogens, and antioxidants - In vivo evidence - Abstract February 3, 2012
Penile metastasis of prostatic adenocarcinoma. Case report - Abstract February 3, 2012
Bone scan index: A quantitative treatment response biomarker for castration-resistant metastatic prostate cancer - Abstract February 3, 2012
An opposed matched field IMRT technique for prostate cancer patients with bilateral prosthetic hips - Abstract February 3, 2012
A study of segment weight optimization with the CMS XiO step-and-shoot IMRT technique for prostate cancer - Abstract February 3, 2012
Quality of life issues in men undergoing androgen deprivation therapy: A review - Abstract February 3, 2012
Impact of androgen deprivation therapy on sexual function - Abstract February 3, 2012
Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer - Abstract February 3, 2012
Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: Prospective evaluation within ProtecT study - Abstract February 3, 2012
Active surveillance in prostate cancer - Abstract February 3, 2012
PCA: Prostate cancer, patient-centred approach or both? - Abstract February 3, 2012
GU Cancers Symposium 2012 - Approved agents and related trials - Session Highlights February 3, 2012
GU Cancers Symposium 2012 - Sequencing of therapies in men with castration-resistant prostate cancer - Session Highlights February 3, 2012
GU Cancers Symposium 2012 - Castration-resistant prostate cancer: Novel targets, agents, and trials - Session Highlights February 3, 2012
GU Cancers Symposium 2012 - A Randomized phase II study of OGX-427 + prednisone vs. prednisone alone in patients with chemotherapy-naive metastatic castration resistant prostate cancer - Poster February 3, 2012
GU Cancers Symposium 2012 - Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort - Poster February 3, 2012
Myriad’s Prolaris® test shown to significantly predict biochemical recurrence risk after prostatectomy February 3, 2012
GU Cancers Symposium 2012 - Role of dose escalation and supplemental androgen deprivation - Session Highlights February 3, 2012
Page 1217 of 1335
  • Start
  • Prev
  • 1212
  • 1213
  • 1214
  • 1215
  • 1216
  • 1217
  • 1218
  • 1219
  • 1220
  • 1221
  • Next
  • End
  • About UroToday
  • Journals
  • Calendar
  • Editorial and Advertising Guidelines
  • Editors and Contributors
  • FAQs
  • Privacy Policy
  • Terms of Use
Follow UroToday

COPYRIGHT © 2002 - 2023 DIGITAL SCIENCE PRESS, LLC

Login

Login to update email address, newsletter preferences and use bookmarks.

  • Forgot Password?
  • Sign Up Free